NCT03321643View on ClinicalTrials.gov

Testing the Addition of an Immunotherapy Agent, Atezolizumab, When Given With the Usual Chemo-Immunotherapy Drug Combination (Rituximab Plus Gemcitabine and Oxaliplatin) for Relapsed/Refractory (That Has Come Back or Not Responded to Treatment) Transformed Diffuse Large B-Cell Lymphoma

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

September 18, 2018

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2026

Conditions
Recurrent Diffuse Large B-Cell LymphomaRecurrent Transformed Non-Hodgkin LymphomaRefractory Diffuse Large B-Cell LymphomaRefractory Transformed Non-Hodgkin LymphomaRichter SyndromeTransformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
Interventions
DRUG

Atezolizumab

Given IV

PROCEDURE

Biopsy Procedure

Undergo biopsy

PROCEDURE

Biospecimen Collection

Undergo collection of blood samples

PROCEDURE

Bone Marrow Biopsy

Undergo bone marrow biopsy

PROCEDURE

Computed Tomography

Undergo CT or PET-CT

DRUG

Gemcitabine

Given IV

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI

DRUG

Oxaliplatin

Given IV

PROCEDURE

Positron Emission Tomography

Undergo PET-CT

BIOLOGICAL

Rituximab

Given IV

Trial Locations (4)

30322

Emory University Hospital/Winship Cancer Institute, Atlanta

91010

City of Hope Comprehensive Cancer Center, Duarte

92093

UC San Diego Moores Cancer Center, La Jolla

95817

University of California Davis Comprehensive Cancer Center, Sacramento

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH